These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16357200)

  • 1. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.
    Lee JH; Canny MD; De Erkenez A; Krilleke D; Ng YS; Shima DT; Pardi A; Jucker F
    Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18902-7. PubMed ID: 16357200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of binding between a therapeutic RNA aptamer and its protein target VEGF: A molecular dynamics study.
    Kalathingal M; Rhee YM
    J Comput Chem; 2023 Apr; 44(11):1129-1137. PubMed ID: 36625560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between structural flexibility and function in the C-terminal region of the heparin-binding domain of VEGF165.
    Jeong KW; Jeong MC; Jin B; Kim Y
    Biochemistry; 2013 Dec; 52(49):8823-32. PubMed ID: 24274376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imino proton exchange rates imply an induced-fit binding mechanism for the VEGF165-targeting aptamer, Macugen.
    Lee JH; Jucker F; Pardi A
    FEBS Lett; 2008 Jun; 582(13):1835-9. PubMed ID: 18485899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing high affinity sequences of DNA aptamer against VEGF165.
    Kaur H; Yung LY
    PLoS One; 2012; 7(2):e31196. PubMed ID: 22359573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study.
    Krilleke D; Ng YS; Shima DT
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1201-6. PubMed ID: 19909247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of a heparin-binding domain of VEGF(165) complexed with its inhibitor triamterene.
    Jeong KW; Lee JY; Lee SA; Yang SP; Ko H; Kang DI; Chae CB; Kim Y
    Biochemistry; 2011 Jun; 50(22):4843-54. PubMed ID: 21545128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular interaction studies of vascular endothelial growth factor with RNA aptamers.
    Zhang X; Yadavalli VK
    Analyst; 2010 Aug; 135(8):2014-21. PubMed ID: 20563342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism.
    Wijelath ES; Rahman S; Namekata M; Murray J; Nishimura T; Mostafavi-Pour Z; Patel Y; Suda Y; Humphries MJ; Sobel M
    Circ Res; 2006 Oct; 99(8):853-60. PubMed ID: 17008606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
    Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP
    Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.
    Héroult M; Bernard-Pierrot I; Delbé J; Hamma-Kourbali Y; Katsoris P; Barritault D; Papadimitriou E; Plouet J; Courty J
    Oncogene; 2004 Mar; 23(9):1745-53. PubMed ID: 15001987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-ExSELEX stabilization of an unnatural-base DNA aptamer targeting VEGF165 toward pharmaceutical applications.
    Kimoto M; Nakamura M; Hirao I
    Nucleic Acids Res; 2016 Sep; 44(15):7487-94. PubMed ID: 27387284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity.
    Yang SP; Kwon BO; Gho YS; Chae CB
    J Neurochem; 2005 Apr; 93(1):118-27. PubMed ID: 15773911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Selection of New DNA Aptamers for Human Vascular Endothelial Growth Factor 165.
    Manochehry S; Gu J; McConnell EM; Salena BJ; Li Y
    Chembiochem; 2020 Jul; 21(14):2029-2036. PubMed ID: 32180322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
    Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
    Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RNA aptamer inhibiting human vesicular endothelial growth factor receptor 1 without affecting cytokine binding.
    Ohuchi SP; Shibuya M; Nakamura Y
    Biochemistry; 2013 Apr; 52(13):2274-9. PubMed ID: 23442158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery.
    Van Bergen T; Vandewalle E; Van de Veire S; Dewerchin M; Stassen JM; Moons L; Stalmans I
    Exp Eye Res; 2011 Nov; 93(5):689-99. PubMed ID: 21907194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics-based model of VEGF-A and its heparin interactions.
    Uciechowska-Kaczmarzyk U; Babik S; Zsila F; Bojarski KK; Beke-Somfai T; Samsonov SA
    J Mol Graph Model; 2018 Jun; 82():157-166. PubMed ID: 29738889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green.
    Zhang X; Potty AS; Jackson GW; Stepanov V; Tang A; Liu Y; Kourentzi K; Strych U; Fox GE; Willson RC
    J Mol Recognit; 2009; 22(2):154-61. PubMed ID: 19195013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain.
    Krilleke D; DeErkenez A; Schubert W; Giri I; Robinson GS; Ng YS; Shima DT
    J Biol Chem; 2007 Sep; 282(38):28045-56. PubMed ID: 17626017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.